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Microfibril-associated glycoprotein-1 (MAGP-1) is
a component of vertebrate extracellular matrix
(ECM) microfibrils that, together with the fibrillins,
contributes to microfibril function. Many of the
phenotypes associated with MAGP-1 gene
inactivation are consistent with dysregulation of the
transforming growth factor β (TGFβ)/bone
morphogenetic protein (BMP) signaling system.
We have previously shown that full-length MAGP1 binds active TGFβ-1 and some BMPs. The work
presented here further defines the growth factor–
binding domain of MAGP-1. Using recombinant
domains and synthetic peptides, along with surface
plasmon resonance analysis to measure the kinetics
of the MAGP-1–TGFβ-1 interaction, we localized
the TGFβ- and BMP-binding site in MAGP-1 to a
19-amino-acid-long, highly acidic sequence near
the N terminus. This domain was specific for
binding active, but not latent, TGFβ1. Growth
factor activity experiments revealed that TGFβ-1
retains signaling activity when complexed with
MAGP-1. Furthermore, when bound to fibrillin,
MAGP-1 retained the ability to interact with TGFβ1, and active TGFβ-1 did not bind fibrillin in the
absence of MAGP-1. The absence of MAGP was
sufficient to raise the amount of total TGFβ stored
in the ECM of cultured cells, suggesting that the
MAGPs compete with the TGFβ large latent
complex for binding to microfibrils. Together, these
results indicate that MAGP-1 plays an active role in
TGFβ signaling in the ECM.

INTRODUCTION
The extracellular matrix (ECM) is a composite
biomaterial that contains informational signals
that influence cell phenotypes. The changing
composition of the ECM during development and
tissue repair provides necessary feedback signals
used by cells to build functional tissues.
Information from the ECM is transmitted to cells
through direct interaction with specific receptors
(e.g., integrins), through mechanical signals that
reflect the material properties of the ECM and
cellular microenvironment, and through
regulation of growth factor accessibility and
signaling. Many ECM proteins bind growth
factors and regulate their activity by providing a
pericellular substrate for presenting growth
factors to specific receptors on cells or by
sequestering active and latent forms away from
the cell for later utilization (1). Growth factors
bind to discrete domains and motifs in ECM
proteins, and there is remarkable specificity to
these binding interactions. As the ECM changes
during development, so does the repertoire of
ECM-associated growth factors that influence
cell phenotypes.
The microfibril is an extracellular matrix
structure made up of fibrillin as the core unit.
Fibrillin appeared early in evolution and, over
time, developed both structural and signaling
functions (2). Fibrillin monomers assemble into
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ABSTRACT

TGFβ binding to MAGP-1 fragments
Our goal in this study was to localize the region
of MAGP-1 that interacts with TGFβ growth
factors. To this end, we performed a set of
surface plasmon resonance (SPR) experiments
where purified TGFβ-1 was injected over
immobilized full-length MAGP-1 or over the
purified truncation fragments coupled to CM-5
sensor chips. Fig 2A shows binding isotherms
for soluble TGFβ-1 interacting with immobilized
full-length MAGP-1 in the SPR-based assay. The
affinity constant calculated using 1:1 Langmuir
binding was 15nM. When tested for binding to
the MAGP-1 fragments, TGFβ-1 bound the
domain 3-4 coupled sensor chip with a slightly
higher affinity than the full-length protein, as
seen in Fig 2B. The affinity constant calculated
using 1:1 Langmuir binding was 3nM. Binding
of TGFβ-1 to domain 4-9 showed substantially

RESULTS
Characterization of recombinant purified fulllength MAGP-1 and MAGP-1 fragments.
Full-length mouse MAGP-1 (exons 3-9) was
expressed in E-coli along with a series of N-
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terminal truncation mutants containing a Nterminal 6-His-tag. The truncations were based
on the exon structure of the gene encoding the
mature molecule shown in Fig 1A (the protein
sequence for mouse MAGP-1 can be found in
supporting information Fig S1). The gene for
MAGP-1 contains nine exons, but only seven
encode the secreted full-length protein. Exon 1 is
untranslated, and exon 2 encodes the majority of
the signal peptide, which is absent from the
mature molecule. After confirming the correct
sequence for each construct by DNA sequence
analysis, the constructs were expressed, and the
proteins purified. The results of the purification
are shown in Fig 1B. The full-length protein has
a predicted mass of 20.6 kDa, but by SDS-PAGE
analysis migrates ~36 kDa. Similarly, the
bacterially expressed domain 3-4 construct has a
predicted mass of ~7.5 kDa but runs at
approximately 16 kDa. Purified domain 4-9 runs
slightly higher than expected (19 kDa compared
to the predicted 17.5 kDa), and the domain 5-9
protein runs true to the predicted mass of ~16
kDa.
Because the MAGP-1 protein and
fragments are expressed in bacteria, the irregular
migration is not due to post-translational
modifications. Anomalous migration of fulllength MAGP-1 on SDS-PAGE has been
described (19). Our results suggest that the
sequence within domains 3-4 is responsible for
this irregular behavior.

fibers of 12-15 nm diameter that provide strength
to tissues by forming fiber bundles. An example
includes the ciliary zonule in the eye, where
microfibrils form the suspensory ligaments that
support the lens (3,4). Microfibrils are also an
important structural component of primitive
vertebrate and invertebrate arteries where they
provide a degree of elastic recoil (5-7).
Another key function of microfibrils is
modulation of growth factor signaling through
fibrillin interactions with the latent TGFβ binding
proteins (LTBPs). LTBPs covalently bind the
small latent complex of TGFβ to form the large
latent TGFβ complex (TGFβ-LLC), which binds
to fibrillin (8,9). By sequestering latent TGFβ in
the matrix, microfibrils indirectly regulate TGFβ
signaling by providing a store of inactive growth
factor that can be utilized through activation by
proteolysis or by mechanical strain (10).
With the arrival of vertebrates in evolution,
new proteins appeared that interact with fibrillin
and modify microfibrillar function.
These
include elastin and microfibril-associated
glycoprotein-1 and -2 (MAGP-1 and MAGP-2).
Elastic fiber formation requires microfibrils (11)
and, because MAGP-1 can bind both tropoelastin
(12,13) and fibrillin (14), the MAGPs were
initially thought to promote the tropoelastinmicrofibril interaction necessary for elastin
assembly. However, inactivation of the genes for
MAGP-1 and MAGP-2 in mice did not affect
elastic fiber formation. Instead, mice lacking
these proteins had abnormalities in bone, fat,
hematopoiesis, and wound healing that were
associated with abnormal TGFβ signaling (1517). We have previously documented a direct
binding interaction between TGFβ family growth
factors and the MAGPs (18), but the sequence
within MAGP that mediates this interaction was
unknown. In this report, we localize the growth
factor-binding domain in MAGP-1 to a sequence
near the protein’s amino terminus and address the
functional consequences of the TGFβ-MAGP
interaction.

lower affinity (190nM), and there was no TGFβ1 binding to a chip coated with domain 5-9 (Fig
2C and 2D, respectively). These results suggest
that the primary binding site for TGFβ-1 is
located in domain 4 of MAGP-1 with an affinity
contribution from domain 3.
TGFβ binds to a 19-residue peptide sequence
spanning domains 3 and 4
Fine mapping of the MAGP-1binding sequence
for TGFβ-1 was done using overlapping synthetic
peptides that spanned the sequence encoded by
exons 3 and 4. Each peptide was purified by
high-pressure liquid chromatography, and the
sequence confirmed by mass spectrometry (data
not shown). Surprisingly, TGFβ-1 failed to bind
to a CM-5 sensor chip coated with a synthetic
peptide made from the sequence of domain 3-4.
The sequence was the same as the bacterially
expressed domain 3-4 peptide except for an Nterminal 6-His-tag on the bacterially expressed
protein. The 6-His-tag itself was not an active
binding sequence since the expressed peptide 5-9
did not bind TGFβ-1 even though it also had a 6His-tag at the amino-terminus
Although unable to bind TGFβ-1 when
bound to a solid substrate, domain 3-4 synthetic
peptide (p1-35) did inhibit binding of TGFβ-1 to
a full-length MAGP-1-coated sensor chip,
thereby establishing its activity (supporting
information Fig S2A). Therefore, for subsequent
mapping studies, we used equilibrium titration
experiments to assess the inhibitory activity of a
series of peptides summarized in Fig 3A. The
peptide based on the first 18 residues of domain
3 (p1-18) showed no inhibitory activity. A
peptide derived from residues 22-36 (p22-36),
and a domain 4 peptide (p26-35) both failed to
inhibit TGFβ-1 binding to full-length MAGP-1
(the inhibitory curve for peptide p22-36 is shown
in supporting information Fig S2B as
representative of no binding inhibition). A
peptide with residues 12-37 (not shown) and a
smaller peptide spanning residues 17-35 (p1735), were both inhibitory.
A detailed investigation into the doseresponse of the smallest peptide with inhibitory
activity (p17-35) is shown in Fig 3B. There is a
dose-dependent decrease in TGFβ-1 binding to
full-length MAGP-1, with half-maximal
inhibition at approximately 30µM p17-35 (Fig

MAGP-1 binds active, but not latent, TGFβ-1
TGFβ is produced as a disulfide-linked
homodimer that is inactive due to the presence of
the N-terminal latency-associated peptide. This
small latent TGFβ complex (SLC) is usually
associated with LTBP1 to produce the large latent
TGFβ complex (LLC), which is covalently bound
to fibrillin-containing microfibrils in the ECM
(9). To determine if MAGP-1 interacts with
latent TGFβ-1, we injected the small latent
complex form of TGFβ-1 over a sensor chip
coated with full-length MAGP-1. As shown in
Fig 4, latent TGFβ-1 at 15nM failed to bind to the
full-length protein. However, after acid activation
for 15 minutes, the same latent TGFβ-1
preparation showed a robust interaction with
MAGP-1.
Neither MAGP-1 nor p17-35 inhibits TGFβ-1
signaling.
To investigate whether TGFβ-1 can still interact
with its cellular receptor when complexed with
MAGP-1, we pre-mixed MAGP-1 or MAGP-1
fragments with active TGFβ-1 and then added the
complex to the reporter cell line MFB-F11. MFBF11 cells are embryonic fibroblasts from Tgfb1-/embryos stably transfected with a reporter
plasmid consisting of TGFβ responsive Smadbinding elements coupled to a secreted alkaline
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3C). These results are consistent with data from
studies with recombinant MAGP-1 fragments
and show that the TGFβ-1 binding activity of
MAGP-1 is defined by a 19 amino acid sequence
in domains 3 and 4. A control peptide with
conformational restraints containing four proline
residues (p17-35pro) failed to inhibit TGFβ-1
binding to full-length MAGP-1 (Fig 3D).
Secondary structure predictions for the
MAGP-1 p17-35 peptide indicated that the
sequence does not have extensive secondary
structure elements, with most residues predicted
to be a random coil (data not shown). IUPred
results predicted a high degree of disorder from
the primary sequence.
PEP-FOLD models
tended to be elongated or compact coils with little
secondary structure. This region of the MAGP-1
protein is likely intrinsically disordered and
cannot adopt an ordered state without binding to
a binding partner such as such as a member of the
TGFβ superfamily.

Predicted MAGP-1 binding site on TGFβ
Molecular docking experiments consistently
placed the MAGP-1 peptide p17-35 in contact
with the finger region of TGFβ-1 (Fig 6). The
peptide prefers to dock near a cluster of positive
residues in this region (R94, K95, and K97) that
are solvent-exposed and, hence, in a position to
attract and bind the negatively charged MAGP-1
peptide. The MAGP-1 peptide remains a highly
flexible coil even when bound, suggesting that
binding occurs through a promiscuous chargecharge interaction between the highly positive
region of TGFβ-1 and the negative residues of
MAGP-1.
The critical positively charged
residues are inaccessible in the inactive TGFβLAP complex, due to the presence of the latency
lasso in the straight-jacket region of the large
latency-associated complex (21). Masking of the
MAGP-1 binding site by the latency peptide
explains why MAGP-1 binds active TGFβ but not
the small latent complex.

BMP-2 binds to the same MAGP-1 sequence
as TGFβ.
Our previous studies found that MAGP-1 bound
to BMP-7 with an affinity approximately equal to
TGFβ (18). To determine whether other BMPfamily members interact with MAGP-1, we
performed SPR experiments with BMP-2. Fig
8A shows BMP-2 binding to MAGP-1 with an
affinity of 25nM. The binding was inhibited by
the active MAGP-1 peptide p17-35, suggesting
that TGFβs and BMPs recognize the same
sequence on the MAGP-1 protein. The control
peptide p17-35pro (Fig 8B) and the N-terminal
peptide p1-18 (not shown) both failed to inhibit
BMP-2 binding to full-length MAGP-1. We were
unable to determine if BMP-2 could form a
ternary complex with fibrillin-2 and MAGP-1
because BMP-2 bound directly to fibrillin-2 with
an affinity of 8nM (supporting information Fig
S4).

MAGP forms a ternary complex with fibrillin2 and TGFβ-1.

Matrix devoid of MAGPs has higher TGFβ
incorporation

Fibrillin interacts with LTBP1 to covalently
anchor the TGFβ large latent complex into the
ECM (9,22). Whether active TGFβ-1 can bind to

The majority of TGFβ in the ECM is in the form
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fibrillin is unclear. To explore a possible binding
interaction between the two proteins, we injected
50nM of active TGFβ-1 over full-length fibrillin2 immobilized on an SPR chip. Fibrillin-2 was
purified from a baculoviral expression system
and showed a single band by SDS-PAGE
(supporting information Fig S3). Fig 7A shows
that no significant interaction was detected
between TGFβ-1 and fibrillin-2. Soluble MAGP1, however, bound tightly to fibrillin-2 with an
apparent affinity constant of 100pM (Fig 7B).
The binding curve fits 1:1 Langmuir binding with
a noticeable slow dissociation rate of -2.64 x 104s1
and a half-life of 2600 seconds. We took
advantage of this slow release rate to follow
MAGP-1 injection onto the fibrillin-2 chip with
50nM of TGFβ-1 and found robust binding of the
growth factor to the fibrillin-2-MAGP-1 complex
(Fig 7C). That MAGP-1 mediated the interaction
was established by inhibiting TGFβ binding with
the active MAGP-1 peptide p17-35 (Fig 7C).
The binding of TGFβ-1 to the MAGP-1-fibrillin2 complex showed similar binding kinetics to
TGFβ-1 binding directly to a MAGP-1-coated
chip (compare the top curve in Fig 3B to Fig 7C).

phosphatase reporter gene (20). The secreted
alkaline phosphatase can be detected with a
chemiluminescent substrate and provides a
sensitive assay for TGFβ activity. We found that
full-length MAGP-1 does not influence TGFβ-1stimulated alkaline phosphatase release from the
MFB-F11 reporter cells when tested over a wide
range of MAGP-1 concentrations (Fig 5A).
Similarly, MAGP-1 peptide p17-35 that blocks
binding of TGFβ-1 to full-length MAGP-1,
presumably by binding to the MAGP-1 binding
site on the growth factor, does not affect the
signaling potential of TGFβ-1 (Fig 5B).
The effects of MAGP-1 on TGFβ activity
were also investigated by assessing changes in
the SMAD signaling pathway in RFL-6 cells. In
agreement with the MFB-F11 reporter cell assay,
pre-incubating TGFβ-1 with soluble MAGP-1
did not inhibit RFL-6 TGFβ-1-stimulated Smad2 phosphorylation (Fig 5C). Fig 5D shows that
Smad-2 phosphorylation is TGFβ dose dependent
in RFL-6 cells with minimal pSmad2 detected in
the absence of TGFβ.

DISCUSSION
The bioavailability of active TGFβ is tightly
regulated at multiple levels, both inside and
outside the cell. It is a crucial regulator of ECM
production (24) yet, in turn, is influenced by the
ECM itself in ways that provide spatiotemporal
control of growth factor activity (1,25,26). In the
ECM, TGFβ family growth factors bind avidly to
sulfated sugars on proteoglycans as well as to
ECM proteins (1,26). Fibrillin-containing
microfibrils are particularly important in
modulating TGFβ signaling and the mechanisms
whereby microfibril-associated proteins regulate
growth factor availability and activity are
complex. We and others have shown that the
fibrillin binding partners MAGP-1 and MAGP-2
work together with fibrillin to modulate TGFβ
availability in the ECM (16,27-29). Mutations in
MAGP genes lead to phenotypes in mice and
humans that are associated with abnormal growth
factor signaling (15,16,18,30-33).
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The MAGPs are functionally defined by
the amino acid composition of their front and
back halves. The back half of MAGP-1 contains
13 cysteine residues, the first seven of which
define the matrix binding domain that mediates
interactions with fibrillin (34,35). The matrix
binding region is the only conserved structural
motif shared with MAGP-2 and is conserved in
all species of MAGP-1 and MAGP-2. The
cysteine-free N-terminal half of MAGP-1 is
acidic, enriched in proline, and contains tyrosine
residues that undergo sulfation and threonine
residues that are sites for O-glycosylation.
Sequences in this region also mediate
noncovalent interactions with tropoelastin
(12,13), the α3 chain of collagen VI (13), decorin
(36), and biglycan (37). While secondary
structure prediction algorithms suggest a random
configuration for the amino terminal sequences,
the absence of cysteine residues, the high
negative charge density, and the binding of
numerous proteins to this area of the molecule
suggests a structure that is accessible and
adaptable.
In this report, we used an overlapping
peptide mapping strategy to localize the growth
factor-binding domain to 19 amino acids in the Nterminal region of MAGP-1. The TGFβ binding
site is contained in domain 4 but requires a part
of domain 3 for full affinity (Fig. 2). The binding
sequence is highly acidic due to four aspartic acid
residues, one glutamic acid, and three tyrosine
residues that are sites for sulfation (with the
sulfate group adding more negative charge). The
acidic residues form a structural repeat, with each
separated by two nonpolar amino acids. The
functional significance of this repeating structure
is not known. The high charge density at this site
resembles characteristics of heparin, which binds
TGFβ with high affinity through negatively
charged sulfated sugars that interact with lysine
residues on TGFβ (38). In fact, the predicted
MAGP-1 binding site on TGFβ is the same as that
postulated for heparin (38,39). While the charged
residues in MAGP-1 are important for growth
factor binding, there are conformational and
flexibility requirements as well, since the
biologically active p17-35 peptide no longer
interacts with TGFβ when prolines are inserted to
introduce structural constraints.
MAGP-1 is one of the few matrix proteins

of the large latent complex bound to fibrillin.
MAGP-1 and the large latent complex bind to the
same region of fibrillin (23), suggesting a
possible competition between the two proteins for
binding to microfibrils. To determine if the
absence of MAGP allows for more latent
complex to accrue in the ECM, we compared total
and active TGFβ levels in cultures of fibroblasts
from WT and MAGP knockout cells. Because
MAGP-2 can also bind TGFβ (16) and might
compensate in the absence of MAGP-1, we
evaluated TGFβ levels in MAGP-1 and MAGP-2
knockout MEFs as well as MEFS from MAGP1;MAGP-2 double knockout mice. After 14 days
of culture, there was 2-3 times more total (latent
plus active) TGFβ activity in acid-activated cellECM extracts of all MAGP knockout cells
compared to WT (Fig 9 black bars). TGFβ
activity detected without acid activation
(indicative of active TGFβ) was also increased in
the single knockout cell lines but was
significantly lower in the double knockout MEFS
(Fig 9 gray bars). Quantitative PCR confirmed
that TGFβ expression was similar for WT and
MAGP knockout cells. Cell number was also
equivalent for all cell types (supporting
information Fig. S5).

EXPERIMENTAL PROCEDURES
Materials:
Carrier-free active TGFβ-1 (7666-MBCF), BMP-2 (355-BM-010/CF) and latent TGFβ1 (299-LT) were purchased from R&D systems,
Minneapolis, MN. Antibodies to MAGP-1 and
fibrillin-2 have been described (36,47,48).
Simply Blue Coomassie G-250 was obtained
from Thermo Fisher scientific. Antibodies to
Smad2/3 (5678S) and phospho-Smad2 (18338S)
were from Cell Signaling, Danvers, MA.
Cell culture and TGFβ-1 activity assay:
The TGFβ reporter cell line MFB-F11 was
a generous gift from Tony Wyss-Coray, Stanford
University. The cells were routinely cultured in
DMEM supplemented with non-essential amino
acid, 10% fetal calf serum, and 100µg/ml
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TGFβ with MAGP-1 does not alter the growth
factor’s signaling potential, nor does an
association between MAGP-1 and fibrillin alter
MAGP-1’s ability to bind TGFβ. Thus, activated
TGFβ bound to MAGP-1 on microfibrils is
capable of signaling when interacting with its
receptor on cells and does not require an
additional activation step to do so.
It is noteworthy that the absence of MAGP1 or MAGP-2 (or both) is sufficient to raise the
amount of total TGFβ stored in the ECM of
cultured cells. This finding is consistent with
studies by Massam-Wu et al. (23), who showed
the MAGP-1 could directly compete with LTBP1 for binding to fibrillin. In the absence of
MAGP, one would, therefore, expect more total
TGFβ to be associated with the ECM, which is
what we found using MAGP knockout cells.
Importantly, the presence of latent but not active
TGFβ in the ECM of MAGP-1:MAGP-2 double
knockout cells suggests that in the absence of the
MAGPs, active TGFβ is not retained in the
matrix.
The mechanistic and functional mapping
studies described in this report, together with our
previous characterization of MAGP knockout
mouse phenotypes indicating increased TGFβ
activity, provide strong evidence for regulation of
the TGFβ pathway as one of MAGP’s major
functional roles in tissues.

that binds active TGFβ without the involvement
of glycosaminoglycans. Some ECM proteins,
such as fibronectin, thrombospondin, fibulins,
tenascins, and fibrillins, bind the large latent
complex form of TGFβ through interaction sites
on the LTBPs (9,40-43), although several bind
the active isoform as well. In general, binding
sites on matrix proteins for active TGFβ are not
well characterized, but the properties of the
MAGP-1 growth factor binding domain may be
instructive for identifying active sequences in
these as well as other proteins. The microfibrillar
protein emilin-1, for example, binds specifically
to the proTGFβ precursor and prevents its
maturation by furin convertases (44). Growth
factor binding activity was mapped to the
protein’s EMI domain, but the precise sequence
was not identified nor is it clear whether the
interaction is with the active or latent regions of
the growth factor. Similarly, TGFβ binding
activity in the matricellular protein SPARC was
localized in one study to the last 37 amino acids
in the carboxy-terminal EC domain (45), but
other work found that SPARC interacted with
TGFβ only when bound to its cognate type II
receptor (46). Interestingly, both emilin-1 and
SPARC have clusters of acidic amino acids in the
putative TGFβ binding regions that create a
negatively charged sequence similar to the
growth factor binding domain in MAGP-1.
Our mapping studies create a clearer
picture of the functionality of the MAGP-1 amino
terminus. The first four amino acids in the TGFβ
binding peptide p17-35 overlap with the last four
amino acids of a peptide used to define the
binding site for tropoelastin and collagen VI
(amino acids 12-21 in our numbering scheme)
(13). It is not known, however, if TE or collagen
VI can affect the binding of TGFβ. Although this
amino-terminal region seems to be available to
interact with numerous proteins noncovalently,
there is a specificity to the binding since MAGP1 does not bind TGFβ3, collagens I, II, or V,
FGF9, FGF21 or the cytokines TNFα, IL-4, IL13, and RANKL (13,17).
Our finding that MAGP-1 binds active
TGFβ but not the small latent precursor form of
the growth factor suggests that MAGPcontaining microfibrils have the potential to store
active TGFβ in addition to the large latent form
that covalently binds to fibrillin. Association of

hydrolyzed in 6N HCl for 48 hours, and amine
content measured with ninhydrin (50).

hygromycin B (Invitrogen, Carlsbad CA). On the
afternoon before an assay, the cells were split into
a 96 well assay plate (4 x 104 cells per well) and
cultured overnight in the absence of hygromycin.
For the assay, cells were rinsed in DMEM then
incubated for 1 hour in DMEM-BSA (DMEM +
1.0 mg/ml heat-denatured BSA). To determine if
MAGP-1 or the p17-35 peptide inhibits TGFβ
signaling, TGFβ (80pM) was mixed with varying
concentrations of MAGP-1 protein or p17-35
peptide in DMEM-BSA for 30 minutes at room
temperature then incubated with the reporter cells
for 24 h. Soluble alkaline phosphatase released
into the media in response to TGFβ was measured
using the Phospha-Light™ SEAP Reporter Gene
Assay System (Life Technologies).
MEF and MFB-F11 co-culture
Levels of active and total TGFβ in the ECM
of cultured MEFs were assessed using established
methods (20,49). Embryonic fibroblasts from
wild type and MAGP-1 knockout mice were
generated from explants as previously described
(18). Early passage cells (passage 4 or less) were
maintained in DMEM with 10% fetal calf serum
supplemented with non-essential amino acids and
routinely passaged 1:3 at confluence. For growth
factor measurements, cells were plated at
confluence in replicate 12 well tissue culture
dishes and maintained for 14 days prior to TGFβ
assays. The cells were rinsed with PBS and
incubated for 1 hr in DMEM containing 1 mg/ml
of heat denatured BSA. For measurement of
active TGFβ levels, approximately 1x105 MFBF11 reporter cells in DMEM-heat denatured BSA
were added to the cultured MEF cells and
incubated overnight. Supernatant from this coculture was assayed for alkaline phosphatase
using the Phospha-Light™ SEAP Reporter Gene
Assay System (Life Technologies).
To determine total protein and total TGFβ,
MEF cells were rinsed with PBS and the cell layer
incubated in 250 µl 0.2M HCl per well for 1 hour
on ice. An aliquot was removed for total protein
determination and the remaining solution
neutralized by the addition of an equimolar
amount of NaOH. The cell-layer extract was
diluted 1:100 in DMEM containing 1mg/ml heat
denatured BSA and assayed for TGFβ using
MFB-F11 cells as described above. The samples
taken for protein determination were dried,

MAGP-1 recombinant expression constructs:
Mouse MAGP-1 cDNA was amplified
from a full-length clone (IMAGE:5249342) using
a forward primer with a SphI restriction site
added to the 5’end (full-length forward primer
with Sph1) and a reverse primer with SacI
restriction site added to 3’ end (full-length
reverse primer with SacI).
The resultant
amplification product along with pQE31 was
digested with SphI and SacI, gel purified, and
appropriate bands ligated. The ligation mix was
used to transform the M15 strain of E-coli, and a
bacterial colony containing a plasmid with the
appropriate sequence was used for expression.
A fragment of MAGP-1 representing
domains 3-4 was amplified from the full-length
pQE31 construct using a forward primer
(truncation forward) from pQE31 sequence and a
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Smad2 phosphorylation:
RFL-6 cells were plated at a confluent
density and incubated overnight in Ham’s F12
medium containing 0.5% horse serum followed
by a 1-hour incubation with Ham’s F12
containing 0.1mg/ml heat denatured BSA to
decrease background TGFβ activity. TGFβ-1
(50pM) was mixed with 0, 0.4, 20, or 1000nM
MAGP-1 in Ham’s F12 containing 0.1mg/ml heat
denatured BSA for 1 hour at 37°C then added to
the RFL-6 cells for 15 minutes. Cells were lysed
in buffer containing 20mM Tris, pH 7.5,
150mM NaCl, 1mM EDTA, 1mM EGTA, 1%
Triton X-100, 2.5mM sodium pyrophosphate,
1mM β-glycerophosphate,
1mM Na3VO4,
1mM NaF 1× protease inhibitor (Roche Applied
Science). Lysates were cleared by centrifugation,
and protein concentration determined. Eight µg
of lysate was run per lane on 10% SDS-PAGE
gels then transferred to nitrocellulose
membranes. Membranes were blocked in 1%
casein then incubated overnight with the
indicated primary antibodies. Antibodies were
detected with secondary antibodies conjugated to
horse radish peroxidase and visualized using
chemiluminescent
substrate
(Millipore
WBKLS0100). The standards used were
Precision Plus Dual Color protein standards
(Biorad 161-0374)

proteins were isolated with nickel resin
chromatography. Proteins were refolded on the
column (51), and eluted with a 0-300mM
imidazole gradient in 50mM TRIS pH7.4.
Fractions were analyzed by SDS-PAGE, and
fractions containing protein were dialyzed
against water and lyophilized. The fusionproteins were further purified using HPLC over a
PRP-3 reverse-phase column using a 0-30%
acetonitrile gradient in 0.05% triethylamine. The
protein content of purified proteins was
determined by absorbance at 280nm using an
extinction coefficient based on the protein
sequence (DNAstar, Madison WI). The purity of
the expressed proteins was assessed using SDSPAGE with reducing (10mM DTT) sample buffer
on 8-25% gradient Phastgels (GE Healthcare Life
Sciences Pittsburgh, PA) and stained with Simply
Blue (Invitrogen). Peptides were synthesized by
Genscript (Piscataway, NJ) and further purified
using HPLC over a PRP-3 reverse-phase column
using a 0-30% acetonitrile gradient in 0.05%
triethylamine. Fractions were dried and analyzed
by amino acid analysis.
RNA isolation and quantitative PCR:
RNA was isolated using a RNeasy kit
(Qiagen74104) after cell homogenization using
QIAshredder (Qiagen 79656). cDNA was
generated using the high capacity RNA-to-cDNA
kit (Applied Biosystems 4387406). Quantitative
PCR was performed on a ViiA7 (Applied
Biosystems) using reagents and taqman probes
supplied by Applied Biosystems for GAPDH
(Mm99999915G1)
and
TGFβ
(Mm01178820_m1).
Quadruplicate
measurements from 100ng RNA were performed
for each sample.

Peptides, protein expression and purification:
6-His-tagged fusion proteins were
expressed and purified using the Qiagen
expression system (Qiagen Inc. Valencia, CA).
Bacteria expressing full-length or truncated
protein were expanded, and while in log-phase,
induced with IPTG at 1mM final concentration
for 4 hours at 30oC. The bacteria were collected
by centrifugation, extracted overnight at 4oC with
gentle agitation in TRIS-phosphate buffered urea
(8M pH8.0) containing protease inhibitors. After
clarifying the extract by centrifugation (12,000xg
for 20 minutes), recombinant 6-His containing

Purification of Fibrillin-2
Fifty ml of serum-free conditioned medium
from SF-9 cells expressing full-length fibrillin-2
(manuscript in preparation) was applied at a flow
rate of 4ml/min onto a 1.0 x 9.5 cm Source 15Q
strong anion exchange column (GE Healthcare)
at room temperature using a Pharmacia FPLC
system. The column was washed with 50ml
buffer A (buffer A: 25mM HEPES, 0.1mM
CaCl2 pH7.4) followed by a 10ml gradient from
0-25% buffer B (buffer B: 25mM HEPES,
0.1mM CaCl2, 1.0M NaCl pH7.4). Fibrillin-2,
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reverse primer from the MAGP-1 sequence
containing a SacI restriction site (Exon 4 reverse
with SacI). The amplification product, along
with pQE31 was digested with EcoRI and SacI,
gel purified, and appropriate bands extracted and
ligated. Fragments for domain 4-9 and 5-9
truncations were amplified from the full-length
construct using a reverse primer from pQE31
(truncation reverse) sequence and a forward
primer from MAGP-1 sequence containing a
BamHI restriction site (exon 4 forward with
BamH1 or exon 5 forward with BamHI). The
amplification products were digested along with
pQE31 with BamHI and SacI, gel purified, and
the appropriate bands ligated. The ligation mix
from each construct was used to transform M15
E. coli. Colonies were picked from the
transformations and sequence verified. The
primer sequences used to construct 6-His fulllength and truncated MAGP-1 are:
Full-length forward primer with Sph1:
TAGCATGCTCAGGGCCAATATGACCTGG
A,
Full-length reverse primer with SacI:
TAGAGCTCCTAGCAGCCCCCACAGCTCC
TG
Truncation forward:
CACACAGAATTCATTAAAGAGGAG
Exon 4 reverse with SacI:
CAGAGCTCTCTTGGTAGTCATAGTAGTCT
G
Exon 4 forward with BamH1
CAGGATCCTGACAACGCAGACTACTATG
Exon 5 forward with BamH1:
CAGGATCCAGAAGTGAGTCCTCGG
Truncation reverse:
TTAAGCTTGGCTGCAGGT

1 injected was 60ul, and the flow rate was
20ul/minute. The precise localization of the
growth factor binding site in MAGP-1 was
determined using inhibition of TGFβ-1 binding to
full-length MAGP-1 by synthetic peptides.
These experiments and the latent TGFB binding
studies were performed on a Reichert SR7000DC
SPR system. Full-length MAGP-1 was coupled
to a carboxymethyl dextran hydrogel surface
sensor chip using the same coupling conditions
used for the Biacore CM-5 chip. TGFβ-1 or
BMP-2 (50nM final concentration) was mixed
with varying concentrations of MAGP-1
synthetic peptide at room temperature for at least
15 minutes prior to injection. The flow rate for
the localization studies was 50 µl/minute, and the
injection volume was 100ul.
Latent TGFβ-1 (5uM stock solution) was
diluted to 15nM in HBST and injected over the
MAGP-1 chip. To activate the latent TGFβ-1,
HCl was added to the latent TGFβ-1 stock
solution to a final concentration of 100mM for 15
minutes at room temperature followed by
neutralization with the addition of an equimolar
concentration of NaOH. The activated TGFβ-1
was diluted to 15nM in HBST and injected over
the full-length MAGP-1 chip.
In ternary complex studies, fibrillin-2 was
diluted 1:5 in 5mM sodium acetate and coupled
with repeat 250ul injections onto a CM-5
activated and blocked as described above.
Approximately 4000uRIU were coupled to the
chip. Direct binding of TGFβ-1 and BMP-2 to
fibrillin-2 was initially assessed prior to loading
MAGP-1 onto the fibrillin-2 chip. After direct
binding experiments, the chip was recycled, and
MAGP-1 was loaded onto the chip with duplicate
MAGP-1 injections (100ul injection at 500nM)
where approximately 130uRU bound. Binding of
TGFβ-1 and BMP-2 to the complex of fibrillin-2
and MAGP-1 was then re-assessed. No recycling
was performed between injections on the
fibrillin-2 MAGP-1 complex. HBST was used as
the sample dilution buffer as the mobile phase.
Unless otherwise noted, chips were recycled with
50ul injections of 0.2M glycine pH=2.3.

Surface plasmon resonance:
Initial mapping of the TGFβ-1 binding site
in MAGP-1 was accomplished using a Biacore X
to measure the change in surface plasmon
resonance due to the interaction of TGFβ-1 in
solution with expressed full-length MAGP-1 or
truncated MAGP-1 fragments coupled to a CM5
chip. For coupling, the protein was dissolved at
20 µg/ml in 5mM acetate buffer, pH4.5, and
injected for 10 minutes onto a CM5 sensor chip
previously activated for 10 minutes with 0.05M
NHS-0.2M EDC. Reactive sites on the chip were
quenched with 100ul of 100mM ethanolamine
pH=8.0 then the chip was equilibrated in HBST
running buffer (10mM HEPES 150mM NaCl
pH=7.4 containing .01% triton-100). Varying
concentrations of TGFβ-1 diluted in running
buffer were then injected. The volume of TGFβ-

MAGP peptide structure prediction
The MAGP-1 p17-35 region that was
experimentally determined to bind to TGFβ was
analyzed for potential secondary structure and
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which remained bound to the resin, was eluted
with a 50ml 25-50% linear buffer B gradient
before the column was recycled with 15ml 100%
buffer B and 100ml buffer A. The elution stream
was monitored for protein at 228 nm and NaCl
content using conductivity. Each fraction was
assessed for fibrillin-2 using an antifibrillin-2
antibody via dot-blot and densitometry with
ImageJ. The three peak fractions containing
fibrillin-2 were pooled and further purified on a
1.6 cm x 1.6 m Sephacryl S-500 column
(fractionation range 40 - 20,000 KDa)
equilibrated in 25mM HEPES, 125mM NaCl
0.1mM CaCl2 pH7.4. The column flow rate was
1ml/min at 4˚C, and 6ml fractions were collected.
The elution stream was monitored for protein at
280nm and fibrillin-2 content for each fraction
was determined by dot-blot. The final product
was analyzed by SDS-PAGE on a 4%
polyacrylamide gel with Laemmli buffer in the
presence and absence of a reducing agent.
Duplicate gels were either stained with Simply
Blue Coomassie G-250 or transferred to
nitrocellulose and stained for fibrillin-2 by
western blot. The purity of the fibrillin-2 is
shown in supplemental figure 3. The standards
used were Precision plus dual color protein
standards (Bio-Rad inc.). The western blot
detection used a secondary donkey anti-rabbit
antibody-HRP conjugate (Amersham Inc.) that
was visualized on film using a chemiluminescent
substrate (Millipore Corporation).

experimental SPR results from the lab, the
MAGP-1 p17-35 sequence were chosen as
docking candidates. The sequences were treated
as flexible peptides and were docked to the TGFβ
structures using GalaxyDock (62) and CABSdock (63). Predicted structures were evaluated by
score and feasibility. Structures were manually
compared to structures of known TGFβcontaining complexes, specifically receptor
bound TGFβ 3KFD (64) and TGFβ in the large
latent complex 3RJR (65), 5VQP (66). Structures
were visualized using VMD (67) and VMD was
used to generate all images.

disorder. Secondary structure was predicted
using Jpred4 (52), Psipred (53), and DISOPRED
(54). Additionally, the sequence was analyzed
using IUPred2A (55). Structural predictions
were performed using PEP-FOLD and PEPFOLD3 (56,57)
MAGP-TGFβ interaction predictions
TGFβ family structures were downloaded
from the protein data bank 1TGK (58), 4KV5
(59), 1KLA, 1KLC, 1KLD (60). Structures were
edited to delete any additional ligands or binding
partners. When appropriate, structures were
subjected to energy minimization in NAMD (61)
to produce a relaxed structure. Based on
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Figure 1. Domain structure of MAGP-1 and purity of expressed peptides. A) Full-length, secreted,
MAGP-1 protein is encoded by seven exons (exons 3-9). In this report, each exon defines a protein
domain, and truncations used for functional analysis were constructed based on exon boundaries. The
schematic shows the domains included in the recombinant fragments (d followed by exon numbers). B)
SDS-PAGE analysis of recombinant full-length MAGP-1 (FL) and purified truncated peptides shown in
panel A. Proteins were separated on 8-25% Phastgels under reducing conditions and detected with
Coomassie Brilliant Blue. The observed and expected molecular weights of each fragment are described
in the Results section.
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Figure 2. Binding of TGFβ-1 to purified full-length MAGP-1 or MAGP-1 fragments.
A) Graph of isotherms from the binding of TGFβ-1 to a CM5 chip coated with full-length MAGP-1 (2200
resonance units coupled). TGFβ-1 concentrations were, from the top, 100, 66.7, 44.4, 29.6, 19.8, 13.2,
8.8, 5.9, 3.9, 2.6, and 1.7 nM. B-D) show the interaction of TGFβ-1 (400, 200, 80, 67, 27 nM) with 440
resonance units of MAGP-1 domain protein 3-4 (B), with 4300 resonance units of MAGP-1 domain 4-9
(TGFβ-1 concentrations of 120, 60, 48, 24,12 nM) (C), and 400nM TGFβ-1 with 2140 resonance units of
MAGP-1 domain 5-9 (D).
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Figure 3. Fine mapping of TGFβ-1 binding activity in domains 3-4. A) summarizes the inhibitory
activity, the sequence and the location of the peptides tested for inhibition of TGFβ-1 (50nM) binding to
120 units of full-length MAGP-1 coupled to a carboxymethyl dextran hydrogel surface sensor chip
(MAGP-1 chip). B) is a graph of isotherms showing p17-35 dose-dependent inhibition of TGFβ-1 binding
to the MAGP-1-coated chip. C) relates the maximal binding of TGFβ-1 (at 100 seconds) to the MAGP-1
chip in the presence of increasing concentrations of peptide p17-35 (taken from panel B). Isotherms in D)
show that the control peptide p17-35pro (100, 50, 25 and 0 µM) has no inhibitory effect on TGFβ-1
binding to MAGP-1.
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Figure 4. MAGP-1 does not bind latent TGFβ-1. Latent TGFβ-1 (15nM) was injected onto a MAGP1 chip, and no interaction was detected. A second sample of latent TGFβ-1 was treated with 100mM HCl
for 10 minutes at room temperature, neutralized with 100mM NaOH, and then diluted to a final
concentration of 15nM. The binding isotherm shows that the acid-activated TGFβ-1 bound with high
affinity to the MAGP-1 chip. The injection volume was 225 µl, and the flow rate was 50 µl/minute for
both injections.
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Figure 5. MAGP-1 and p17-35 do not block TGFβ-1 signaling. A) Active TGFβ-1 (80pM) was
mixed with the indicated concentrations of MAGP-1, incubated for 15 minutes, and then added to MFBF11 cells for 24 hours. The culture medium was then assayed for alkaline phosphatase activity, which
provides a measure of TGFβ activity. Shown are mean +/- standard deviation, n=8. B) Active TGFβ-1
(80pM) was mixed with 10µM or 100µM p17-35, p17-35pro, or no peptide for 15 minutes and added to
MFB-F11 cells for 24 hours. A control with no added TGFβ-1 was included. The medium was collected
and assayed for alkaline phosphatase activity. Shown are mean +/- standard deviation, n=4. One-way
analysis of variance showed no differences between samples in panels A or B. C) Increasing
concentrations of soluble MAGP-1 were pre-incubated for 1 hour with 50pM TGFβ-1 and the complex
incubated with RFL-6 cell (a fibroblast line that does not make MAGP-1) for 15 minutes. Cell extracts
were then analyzed by western blot for phosphoSmad2 (pSmad-2) (top) and for total Smad2 (tSmad2)
(bottom). The ratio of pSmad2 to tSmad2 is shown in the bottom graph. D) Smad2 phosphorylation in
RFL-6 cells is TGFB-1 dose dependent with minimal baseline phosphorylation. RFL-6 cells were treated
with the indicated dose of TGFβ-1 and levels of phosphorylated Smad-2 (top panel) or total Smad-2
(bottom panel) were determined from cell extracts by western blot analysis. The ratio of pSmad2 to
tSmad2 is shown in the bottom graph.
.
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Figure 6: The structure of TGFβ-1with and without the MAGP-1 p17-35 peptide. Top: Side and top
views of the TGFβ-1 dimer with solvent exposed residues R94, K95, and K97 shown in green. Bottom:
Representative binding of the MAGP-1 p17-35 peptide (shown in black) to TGFβ-1. The MAGP-1
peptide remains largely disordered while consistently interacting with the positive residues in the TGFβ-1
finger region.
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Figure 7. TGFβ-1 binds to fibrillin-2 only in the presence of MAGP-1. A) Purified full-length
fibrillin-2 was covalently coupled (3,000 resonance-units) to a carboxymethyl dextran hydrogel surface
sensor chip (fibrillin-2 chip), and TGFβ-1 was injected at a concentration of 50nM at 25ul per minute for
3.5 minutes. Data show no measurable interaction between the two proteins. B) MAGP-1 (6.2nM for 3.5
minutes at 25µl/min) bound to fibrillin-2 with an apparent affinity of 100pM. C) TGFβ-1 (50nM for 3.5
minutes at 25ul/min) bound to the MAGP-1-fibrillin-2 complex whereas TGFβ-1 pre-incubated with
50µM p17-35 peptide failed to bind to the complex.
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Figure 8. BMP-2 binding localizes to the same domain on MAGP-1 as TGFβ-1. A) shows isotherms
documenting binding of 50nM BMP-2 to a MAGP-1-coated chip. B) Binding was inhibited by
preincubation of BMP-2 with peptide p17-35 from the top 0, 5, 25, and 50uM) but not the control peptide
p17-35pro (0, 5, 25 and 50uM)
.
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Figure 9. MAGP 1 and MAGP-2 modulate TGFB levels in fibroblast ECM. Comparison of total TGFβ
levels (black bars) in 14 day post confluent WT and MAGP knockout cell layers showing significant increases
in total TGFβ in MAGP-1 knockout (**p>0.01, n=3), MAGP-2 knockout (*p> 0.05, n=3), and MAGP1;MAGP-2 double knockout (** p>0.01) fibroblasts. Similarly, active TGFβ levels (grey bars) are significantly
increased in MAGP-1 knockout (* p>.05, n=2) and MAGP-2 knockout (* p>.05, n=3) cells, but are decreased
(** P>.01 n=3) in the double knockouts.
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